Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi Syndrome

Rhythm · Phase 2 · Completed · Enrollment 40

NCT02311673

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
Setmelanotide 0.5 mgn/rn/rn/rn/r
Setmelanotide 1.5 mgn/rn/rn/rn/r
Setmelanotide 2.5 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • Setmelanotide 0.5 mg: endpoint not reported
  • Setmelanotide 1.5 mg: endpoint not reported
  • Setmelanotide 2.5 mg: endpoint not reported
  • Placebo: endpoint not reported